New antiarrhythmic agents for atrial fibrillation and atrial flutter

Expert Opinion on Emerging Drugs

Volumn 10, Issue 2, 2005, Pages 311-322

  Pecini, Redi ^a   Elming, Hanne ^a   Pedersen, Ole Dyg ^b   Torp Pedersen, Christian ^b  

^a Rigshospitalet   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Antiarrythmic agents; Atrial fibrillation; Atrial flutter

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; AMBASILIDE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DOFETILIDE; DRONEDARONE; ENALAPRIL; FLECAINIDE; IBUTILIDE; IRBESARTAN; LOSARTAN; METHYLPREDNISOLONE; NIP 142; NIP 412; PROPAFENONE; QUINIDINE; RS 100302; S 20951; S 9947; SOTALOL; STEROID; TEDISAMIL; TRANDOLAPRIL; UNCLASSIFIED DRUG; VERAPAMIL;

BRADYCARDIA; BRONCHOSPASM; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFECT; FATIGUE; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE TACHYCARDIA; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; INSOMNIA; LIVER TOXICITY; LUNG TOXICITY; NAUSEA; PHLEBITIS; PHOTOSENSITIVITY DISORDER; POLYNEUROPATHY; QT PROLONGATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THYROID DISEASE; TORSADE DES POINTES;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CLINICAL TRIALS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 18844422731     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.2.311     Document Type: Review

References (94)

1. BENJAMIN E, LEVY D, VAZIRI S, D'AGOSTINO R, BELANGER A, WOLF P: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840-844.
2. BENJAMIN E, WOLF P, D'AGOSTINO R, SILBERSHATZ H, KANEL W, LEVY D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98(10):946-952.
3. WOLF PA, MITCHELL JB, BAKER CS, KANNEL WB, D'AGOSTINO RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. (1998) 158:229-234.
4. PEDERSEN O, BAGGER H, KOBER L, TORP-PEDERSEN C: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur. Heart J. (1999) 20:748-754.
5. MIDDLEKAUF H, STEVENSON W, STEVENSON L: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation (1991) 84:40-48.
6. CARSON P, JOHNSON G, DUNKMAN W, FLETCHER R, FARRELL L, COHN J: The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 87:VI102-VI110.
7. KOPECKY S, GERSH B, McGOON M et al.: Lone aerial fibrillation in elderly persons. Arch. Intern. Med. (1999) 159:1118-1122.
8. CHEN S, CHEN Y, YEH H, TAI C, CHEN Y, LIN C: Pathophysiology of the pulmonary vein as an atrial fibrillation initiator. Pace (2003) 26:1576-1582.
9. WIJFFELS M, KIRCHHOF C, DORLAND R, ALLESSIE M. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation (1995) 92(7):1954-1968.
10. LI D, SHINIGAWA K, PANG L et al.: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 104:2608-2614.
11. FUSTER M, RYDEN L, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J. Am. Coll. Cardiol. (2001) 38:1266-1261.
12. WYSE D, WALDO A, DIMARCO J et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
13. VAN GELDER I, HAGENS V, BOSKER HA et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. (2002) 347:1834-1840.
14. CHANNER K: Current management of symptomatic atrial fibrillation. Drugs (2001) 61:1424-1437.
15. NACCARELLI G, DORIAN P, HOHNLOSER S, COUMEL P: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am. J. Cardiology (1996) 77:53A-59A.
16. HOHNLOSER S, VAN DE LOO A, BAEDEKER F: Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J. Am. Coll. Cardiol. (1995) 26:852-858.
17. CAPUCCI A, LENZI T, BORIANI G et al.: Effectiveness of loading oral flecainide for onverting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am. J. Cardiology (1992) 70:69-72.
18. DONOVAN K, POWER B, HOCKINGS B, DOBB G, LEE K-Y: Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am. J. Cardiology (1995) 75:693-697.
19. DONOVAN K, DOBB G, COOMBS L et al.: Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am. J. Cardiology (1991) 67:137-141.
20. BERTINI G, CONTI A, FRADELLA G et al.: Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J. Emerg. Med. (1990) 8:15-20.
21. BOTTO G, CAPUCCI A, BONINI W et al.: Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral dose of propafenone: comparison of two regimens. Int. J. Cardiol. (1997) 58:55-61.
22. BORIANI G, CAPUCCI A, LENZI T, SANGUINETTI M, MAGNANI B: Propafenone for conversion of recent-onset atrial fibrillation. Chest (1995) 108:355-358.
23. STROOBANDT R, STIELS B, HOEBRECHTS R: Propafenone for conversion and prophylaxis of atrial fibrillation. Am. J. Cardiology (1997) 79:418-423.
24. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. (1989) 321(6):405-412.
25. Effect of the antiarrhythmic agent moncizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N. Engl. J. Med. (1992) 327:227-233.
26. ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. N. Engl. J. Med. (2000) 342:913-920.
27. CHUN S, SAGER P, STEVENSON W, NADEMANEE K, MIDDLEKAUF H, SINGH B: Long-term efficacy of amiodarione for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am. J. Cardiology (1995) 76:47-50.
28. KOCHIADAKIS G, IGOUMENIDIS N, MARKETOU M, KALEBOUBAS M, SIMATIRAKIS E, VARDAS P: Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart (2000) 84:251-257.
29. VAN NOORD T, VAN GELDER I, SCHOONDERWOERD B, CRIJNS J: Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm on amiodarone. Am. J. Cardiology (2000) 86:1384-1385.
30. TIELEMAN R, GOSSELINK A, CRIJNS H et al.: Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am. J. Cardiology (1997) 79:53-57.
31. NOC M, STAJER D, HORVAT M: Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am. J. Cardiology (1990) 65:679-680.
32. PEUHKURINEN K, NIEMELA M, YLITALO A, LINNALUOTO M, LILJA M, JUVONEN J: Effectiveness of amiodaroneas a single oral dose for recent-onset atrial fibrillation. Am. J. Cardiology (2000) 85:462-465.
33. CLEMO H, WOOD M, GILLIGAN D, ELLENBOGEN K: Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am. J. Cardiology (1998) 81:594-598.
34. DEEDWANIA P, SINGH B, ELLENBOGEN K, FISHER S, FLETCHER R, SINGH S: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation (1998) 98:2574-2579.
35. SINGH S, FLETCHER R, FISHER S et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. (1995) 333:77-82.
36. VORPERIAN V, HAVIGHURST T, MILLER S, JANUARY C: Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. Cardiol. (1997) 30:791-798.
37. ELMING H, BRENDORP B, PEDERSEN O, KØBER L, TORP-PEDERSEN C: Dofetilide: a new drug to control cardiac arrhythmia. Expert Opin. Pharmacother. (2003) 4(6):973-985.
38. MOUNSEY J, DIMARCO J: Dofetilide. Circulation (2000) 102:2665-2670.
39. SINGH S, ZOBLE R, YELLEN L et al.: Efficacy and safety dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter. Circulation (2000) 102:2385-2390.
40. PEDERSEN O, BAGGER H, KELLER N, MARCHANT B, KØBER L, TORP-PEDERSEN C: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation (2001) 104:292-296,
41. KØBER L, BLOCH THOMSEN P, MØLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356:2052-2058.
42. TORP-PEDERSEN C, MØLLER M, BLOCH-THOMSEN P: Dofetilide in patients with congestive heart failure and left ventricular dysfuction. N. Engl. J. Med. (1999) 341:857-865.
43. NØRGAARD B, WACHTELL K, CHRISTENSEN P et al.: Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation. Am. Heart J. (1999) 137:1062-1069.
44. SUNG R, TAN H, KARAGOUNIS L et al.: Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled sudy. Am. Heart J. (1995) 129(4):739-748.
45. PLEWAN A, LEHMANN G, NDREPEPA G et al.: Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Eur. Heart J. (2001) 22:1504-1510.
46. ROBERTS S, DIAZ C, NOLAN P et al.: Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am. J. Cardiol. (1993) 72:567-573.
47. FARSHI R, KISTNER D, SARMA J, LONGMATE J, SINGH B: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open label study of five drug regimens. J. Am. Coll. Cardiol. (1999) 33:304-310.
48. MURGATROYD F, GIBSON S, BAIYAN X et al.: Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation (1999) 99(21):2765-2770.
49. GALUN E, FLUGELMAN M, GLICKSON M, ELIAKIM M: Failure of long-term digitalisation to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest (1991) 99:1038-1040.
50. RINKENBERGER R, PRYSTOWSKI E, HEGER J, TROUP P, JACKMANN W, ZIPES D: Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation (1980) 62:996-1010.
51. ELLENBOGEN K, DIAS V, CARDELLO F et al.: Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am. J. Cardiol. (1995) 75:45-49.
52. BALSER J, MARTINEZ E, WINTERS B et al.: Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology (1998) 89:1052-1059.
53. COX J, TM S: The surgical management of atrial fibrillation. Ann. Rev. Med. (1997) 48:511-523.
54. COX J, JAQUISS R, SCHUESSLER R, BOINEAU J: Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure. J. Thorac. Cardiovasc. Surg. (1995) 110:485-495.
55. COX J: The surgical treatment of atrial fibrillation. IV. Surgical technique. J. Thorac. Cardiovasc. Surg. (1991) 101:584-592.
56. MELO J, SANTIAGO T, GOUVEIA R, MARTINS A: Atrial ablation for the surgical treatment of atrial fibrillation: principles and limitations. J. Card. Surg. (2004) 19:207-210.
57. AD N, COX J: The Maze procedure for the treatment of atrial fibrillation: a minimally invasive approach. J. Card. Surg. (2004) 19:196-200.
58. MAGNANO A, WOOLLETT I, GARAN H: Percutaneous catheter ablation procedures for the treatment of atrial fibrillation. J. Card. Surg. (2004) 19:188-195.
59. PAPPONE C, ROSANIO S: Evolution of non-pharmacological curative therapy for atrial fibrillation: where do we stand today? Int. J. Cardiol. (2002) 88:135-142.
60. WIESFELD A, TAN E, VAN VELDHUISEN D, CRIJNS H, VAN GELDER I: Radiofrequency of atrial fibrillation. Int. J. Cardiol. (2004) 93(2-3):231-237.
61. MITCHELL A, SULKE N: Does rapid atrial pacing terminate atrial fibrillation? A comparison of laboratory and device termination studies. Card. Electrophysiol. Rev. (2003) 7:352-354.
62. GOLD M, SULKE N, SCHWARTZMAN D, MEHRA R, EULER D: Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J. Cardiovasc. Electrophysiol. (2001) 12:1247-1253.
63. NEWMAN D, DORIAN P, PAQUETTE M: Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am. Heart J. (2003) 145:841-846.
64. BURNS J, SEARS S, SOTILE R et al.: Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study. J. Cardiovasc. Electrophysiol. (2004) 15:286-291.
65. KAY G, BUBIEN R, EPSTEIN A, PLUMB V: Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am. J. Cardiology (1988) 62:741-744.
66. HOHNLOSER S, DORIAN P, STRAUB M, BECKMANN K, KOWEY P: Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol. (2004) 44(1):99-104.
67. NATTEL S, YUE L, WANG Z: Cardiac ultrarapid delayed rectifiers. Cell Physiol. Biochem. (1999) 9:217-226.
68. LI G, FENG J, WANG Z, FERMINI B, NATTEL S: Adrenergic modulation of ultrarapid delayed rectifirer K sup plus current in human atrial myocytes. Circ. Res. (1996) 78(5):903-915.
69. NAGASAWA H, FUJIKI A, FUJIKURA N, MATSUDA T, YAMASHITA T, INOUE H: Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ. J. (2002) 66(2):185-191.
70. WIRTH K, PAEHLER T, ROSENSTEIN B et al.: Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc. Res. (2003) 60:298-306.
71. HEIDBUCHEL H: A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur. Heart J. (2003) 24:2077-2078.
72. FRUSTACI A, CHIMENTI C, PIERONI M: Idiopathic myocardial vasculitis presenting as restrictive cardiomyopathy. Circulation (1997) 111:1462-1464.
73. DERNELLIS J, PANARETOU M: Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. (2004) 25:1100-1107.
74. FISCHBACH P, BARRETT T, GOYAL R et al.: Conversion of atrial fibrillation by the experimental drug tedisamil in two canine models. J. Cardiovasc. Electrophysiol. (2001) 12(10):1138-1144.
75. VAN OPSTAL J, SCHOENMAKERS M, VERDUYN S et al.: Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation (2001) 104:2722-2727.
76. BALÁTI B, IOST N, SIMON J, VARRÓ A, PAPP J: Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agen in canine isolated ventricular muscle and Purkinje fibers. Gen. Pharm. (2000) 34:85-93.
77. CONNOLLY SJ, SCHNELL DJ, PAGE RL, WILKINSON WE, MARCELLO SR, PRITCHETT EL: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. Cardiol. (2001) 88:974-979.
78. WANG J, FENG J, NATTEL S: Class III antiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectivensess between D-sotalol and the new antiarrhythmic drug ambasilide. Circulation (1994) 90(4):2032-2040.
79. PRITCHETT E, PAGE R, CONNOLLY S, MARCELLO S, SCHNELL D, WILKINSON W: Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J. Am. Coll. Cardiol. (2000) 36:794-802.
80. PRATT C, SINGH S, AL-KHALIDI H et al.: The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. J. Am. Coll. Cardiol. (2004) 43:1211-1216.
81. KNOBLOCH K, BRENDEL J, PEUKERT S: Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left versus right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, D,L-sotalol and Ibutilide. Naunyn-Schmiedeberg's Arch. Pharmacol. (2002) 366:482-487.
82. 4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation (1999) 100(19):2010-2017.
83. PEDERSEN O, BAGGER H, KØBER L, TORP-PEDERSEN C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100(4):376-380.
84. GOETTE A, STAACK T, RÖCKEN C et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol. (2000) 35:1669-1677.
85. NAKASHIMA H, KUMAGAI K, HIDENORI U, GONDO N, IDEISHI M, ARAKAWA K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 101(22):2612-2617.
86. BOTTO G, LUZI M, SAGONE A: Atrial fibrillation: the remodelling phenomenon. Eur. Heart J. (2003) 5(Suppl. H):H1-H7.
87. DE SIMONE A, DE PASQUALE M, DE MATTEIS C et al.: Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur. Heart J. (2003) 24:1425-1429.
88. KINEBUCHI O, MITAMURA H, SHIROSHITA-TAKESHITA A et al.: Oral verapamil attenuates the progression of pacing-induced electrical and mechanical remodeling of the atrium. Circ. J. (2004) 68(5):494-500.
89. GERSTENFELD E, GUERRA P, SPARKS P, HATTORI K, LESH M: Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. Cardiovasc. Electrophysiol. (2001) 12:900-908.
90. FRIEDMAN P, DIJKMAN B, WARMAN E et al.: Atrial theraies reduce atrial arrhythmia burden in defibrillatior patients. Circulation (2001) 104:1023-1028.
91. KROL R, SAKSENA S, PRAKASH A: New devices and hybrid therapies for treatment of atrial fibrillation. J. Interv. Card. Electrophysiol. (2000) 4(Suppl. 1):163-169.
92. SAKSENA S, MADAN N: Hybrid therapy of atrial fibrillation: algorithms and outcome. J. Interv. Card. Electrophysiol. (2003) 9:235-247.
93. YOSHIDA T, NIWANO S, INUO K et al.: Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pace (2003) 26:314-317.
94. PEDERSEN O, KØBER L, TORP-PEDERSEN C: Atrial fibrillation and atrial cardiomyopathy - two sides of the same coin? Am. Heart J. (2004) 147:953-955.